Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of Two Formulations of Pegylated Liposomal Doxorubicin in Advanced Ovarian or Metastatic Breast Cancer
NCT07648940Phase 1Completed
- Sponsor
- Zodiac Produtos Farmacêuticos
- Start
- Feb 2023
- Primary completion
- Jun 2023
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of pegylated liposomal doxorubicin in ovarian cancer and breast cancer (2 arms), sponsored by Zodiac Produtos Farmacêuticos. Primary endpoints: Maximum Plasma Concentration at 336 hours and Area Under the Curve from time zero to time t at 336 hours. Started Feb 2023; status: completed.
02
Drugs
pegylated liposomal doxorubicin
03
Conditions
ovarian cancerbreast cancer
Beyond the preview
Go deeper on NCT07648940.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07648940.